NuVasive’s Osteocel Purchase, Spinal Sales Boost Stock 29% In Q2 – Index
This article was originally published in The Gray Sheet
Executive Summary
Investor enthusiasm for spinal device maker NuVasive's May acquisition of the biologic bone matrix product Osteocel, combined with stronger-than-expected corporate sales growth, helped drive NuVasive stock ahead 29% in the second quarter